Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

13.44 3.07

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.89

Max

13.52

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	312K -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+134.25% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-266M 1.1B
Vorige openingsprijs	10.37
Vorige sluitingsprijs	13.44

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 jun 2026, 23:51 UTC

"Bitcoin rises as Ethereum falls amid pivotal AI earnings reports, while U.S. credit rating remains stable and China's industrial profits soar."

27 jun 2026, 23:51 UTC

China's industrial profits rise 18.8% amid AI investments; U.S. credit rating affirmed at AA+ as markets brace for modest growth and pivotal Meta earnings report.

27 jun 2026, 23:51 UTC

Cryptocurrency market shows mixed signals as investors brace for key AI earnings reports and upcoming economic indicators amid cautious U.S. growth outlook.

27 jun 2026, 23:51 UTC

Mixed cryptocurrency performance reflects cautious investor sentiment ahead of key economic indicators and AI earnings reports, while U.S. credit rating remains stable amid inflation concerns.

27 jun 2026, 23:51 UTC

Bitcoin is trading higher since Friday's close, remaining flat during the current session. The price fluctuated within a routine range today.

27 jun 2026, 23:42 UTC

U.S. Labor Force Participation Rate Release on July 2, 2026: Market Cautious Amid Declining Employee Confidence and Legislative Changes Impacting Employment Dynamics.

27 jun 2026, 23:42 UTC

Market Awaits BoC Governor Macklem's Speech on Interest Rate Policy Amid Economic Uncertainties

27 jun 2026, 23:42 UTC

Market Eyes BoE Governor Bailey's July Speech for Insights on UK Interest Rates Amid Global Monetary Policy Shifts.

27 jun 2026, 23:42 UTC

Market Anticipates 0.3% Increase in U.S. Average Hourly Earnings Amid Wage Growth Concerns and Inflation Pressures Ahead of July Release.

27 jun 2026, 23:42 UTC

U.S. Unemployment Rate Release on July 2, 2026 Expected at 4.3%, Amid Concerns Over Employee Confidence and Potential Minimum Wage Legislation Impacting Markets

27 jun 2026, 23:42 UTC

Market Anticipates 114K Job Additions in Upcoming June NFP Report Amid Mixed Economic Sentiment and Inflation Concerns.

27 jun 2026, 23:42 UTC

Market Awaits Key Average Hourly Earnings Data Amidst Rising Inflation Concerns and Potential Federal Reserve Rate Implications on July 2, 2026.

27 jun 2026, 23:31 UTC

Mexican Consumer Confidence Expected to Remain Low Amid Economic Challenges Ahead of July 3 Data Release.

27 jun 2026, 23:11 UTC

ADP Employment Change Report Forecasts 118,000 Job Increase Amid Cautious Optimism in Labor Market Ahead of July Release.

27 jun 2026, 23:11 UTC

Correlated Moves

S&P 500 Index declines in after-market trading, reflecting cautious sentiment ahead of upcoming earnings reports from AI-linked companies like Meta.

27 jun 2026, 23:11 UTC

Correlated Moves

The Russell 2000 Index is lower in after-market trading, reflecting broader market sentiment amid upcoming earnings reports from AI-linked companies.

27 jun 2026, 23:11 UTC

Correlated Moves

The Dow Jones Index is lower in after-market hours, reflecting unusual trading activity and broader declines seen in the Russell 2000 Index.

27 jun 2026, 23:11 UTC

The FTSE 100 Index is lower in after-market hours, reflecting a dip since Friday's close. Anticipation of corporate earnings reports may influence market sentiment.

27 jun 2026, 23:11 UTC

Correlated Moves

The Nasdaq 100 Index is lower during after-market hours, continuing a downward trend since Friday's close amid broader market weakness and upcoming earnings anticipation.

27 jun 2026, 23:02 UTC

Canada's May GDP report set for June 30, with a projected growth of 0.4% amid mixed stock performance and trade uncertainties.

27 jun 2026, 22:32 UTC

Germany's June 30 inflation rate forecasted to rise by 0.1%, raising concerns over persistent inflation and potential ECB monetary policy shifts amid global economic pressures.

27 jun 2026, 22:32 UTC

Germany's June 2026 Inflation Rate Release Expected at 2.5% Amid Rising Global Price Pressures and Cautious Market Sentiment

27 jun 2026, 22:32 UTC

Japan's Tankan Large Manufacturers Index set for June 30, with cautious market sentiment amid stock declines and mixed economic signals.

27 jun 2026, 22:32 UTC

South Africa's Upcoming Balance of Trade Data Expected to Show Significant Shift Amid Rising Imports and Mixed Export Performance

27 jun 2026, 22:21 UTC

Brazil's Central Bank to Provide Key Insights on Interest Rate Outlook Amid Rising Global Pressures in June 29 Readout.

27 jun 2026, 22:11 UTC

Japan's Industrial Production Expected to Rise 1.1% in May Amid Mixed Market Sentiment and Economic Concerns

27 jun 2026, 22:02 UTC

South Korea's June 2026 Inflation Rate Release Sparks Market Caution Amid Rising Price Pressures and Regional Economic Concerns.

27 jun 2026, 21:51 UTC

Japan's Retail Sales YoY data for May set to release on June 28, with a projected growth of 3.2% amid mixed market sentiment and inflation concerns.

27 jun 2026, 21:51 UTC

Japan's Unemployment Rate Expected to Stabilize at 2.5% Amid Mixed Economic Sentiment and Market Volatility

27 jun 2026, 21:41 UTC

Cautious Sentiment Surrounds Upcoming Ai Group Industry Index Release Amid Ongoing Economic Challenges in Australia

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

134.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 134.25%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.